Safety of statin therapy in patients with mitochondrial diseases

J Clin Lipidol. 2013 Mar-Apr;7(2):182. doi: 10.1016/j.jacl.2012.08.003. Epub 2012 Aug 10.

Authors

Fady Hannah-Shmouni, Ahmad Al-Sarraf, Jiri Frohlich, Michelle M Mezei, Sandra Sirrs, Andre Mattman

PMID: 23415441
DOI: 10.1016/j.jacl.2012.08.003

No abstract available

Publication types

Letter

MeSH terms

Atorvastatin
Heptanoic Acids / adverse effects
Heptanoic Acids / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hypercholesterolemia / drug therapy
Mitochondrial Diseases / diagnosis*
Mitochondrial Diseases / epidemiology
Mitochondrial Diseases / etiology
Pyrroles / adverse effects
Pyrroles / therapeutic use

Substances

Heptanoic Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pyrroles
Atorvastatin